Colchicine reduces inflammation in a humanized transgenic murine model of sickle cell disease

Haematologica. 2024 Jan 1;109(1):308-311. doi: 10.3324/haematol.2023.283377.

Authors

Raghda T Fouda¹, Hemanth M Cherukury¹, Stacy B Kiven¹, Natalie R Garcia¹, Donovan A Argueta¹, Graham J Velasco², Kalpna Gupta³, John D Roberts⁴

Affiliations

¹ Hematology/Oncology, Department of Medicine, University of California, Irvine, CA.
² Pathology Department, VA Long Beach Medical Center, Long Beach, CA.
³ Hematology/Oncology, Department of Medicine, University of California, Irvine, CA, USA; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN. kalpnag@hs.uci.edu.
⁴ Yale University. john.d.roberts@yale.edu.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anemia, Sickle Cell* / drug therapy
Anemia, Sickle Cell* / genetics
Animals
Colchicine* / pharmacology
Colchicine* / therapeutic use
Disease Models, Animal
Humans
Inflammation / drug therapy
Inflammation / genetics
Mice
Mice, Transgenic

Substances

Colchicine

Grants and funding